MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18–60 years of age) with chronic diseases who are at risk of post-influenza complications

Baldo, Vincenzo; Baldovin, Tatjana; Floreani, Annarosa; Carraro, Amedeo; Trivello, R.

doi:10.1016/j.vaccine.2007.02.045

Cited by 62 publications

(44 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vaccines with MF59 adjuvant could represent a new tool for the prevention of influenza in subjects with reduced immune responsiveness, such as HIV-infected individuals (17,24), elderly people (13,19,31,38,44), and those with underlying chronic debilitating diseases (3,4), as recently demonstrated by other authors. Additional studies with this vaccine are required in order to better evaluate the magnitude and duration of both the humoral and cell-mediated responses driven by MF59 adjuvant in various population groups.…”

Section: Discussionmentioning

confidence: 63%

“…The availability of influenza virus vaccines with adjuvants, such as those containing the oil-in-water emulsion MF59, has recently opened new, interesting perspectives for the prevention of the disease, not only in elderly subjects but also in adults belonging to well-recognized risk categories (3,4,17,24). Several studies of the elderly have demonstrated the higher immunogenicity of influenza virus vaccines with MF59 adjuvant than of split or subunit vaccines with no adjuvant (13,19,31,38,44).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Safety and Immunogenicity of Two Influenza Virus Subunit Vaccines, with or without MF59 Adjuvant, Administered to Human Immunodeficiency Virus Type 1-Seropositive and -Seronegative Adults

Durando¹,

Fenoglio

Boschini³

et al. 2008

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 63%

mentioning

confidence: 99%

Safety and Immunogenicity of Two Influenza Virus Subunit Vaccines, with or without MF59 Adjuvant, Administered to Human Immunodeficiency Virus Type 1-Seropositive and -Seronegative Adults

Durando¹,

Fenoglio

Boschini³

et al. 2008

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…Therefore, NEadjuvanted vaccines can be used to potentiate the vaccine efficacy and to broaden the spectrum of Ab responses. This feature is important for immunocompromised population, such as patients with chronic infections, older adults and infants/young children who are at risk for postinfluenza complications (30). Collectively, our findings imply that original antigenic sin could potentially be prevented in the naive human population, especially children, by administering adjuvants with the first influenza vaccine.…”

Section: Discussionmentioning

confidence: 67%

Strategies to alleviate original antigenic sin responses to influenza viruses

Kim

Davis

Sambhara

et al. 2012

Proc. Natl. Acad. Sci. U.S.A.

101

View full text Add to dashboard Cite

Original antigenic sin is a phenomenon wherein sequential exposure to closely related influenza virus variants reduces antibody (Ab) response to novel antigenic determinants in the second strain and, consequently, impairs the development of immune memory. This could pose a risk to the development of immune memory in persons previously infected with or vaccinated against influenza. Here, we explored strategies to overcome original antigenic sin responses in mice sequentially exposed to two closely related hemagglutinin 1 neuraminidase 1 (H1N1) influenza strains A/PR/8/ 34 and A/FM/1/47. We found that dendritic cell-activating adjuvants [Bordetella pertussis toxin (PT) or CpG ODN or a squalenebased oil-in-water nanoemulsion (NE)], upon administration during the second viral exposure, completely protected mice from a lethal challenge and enhanced neutralizing-Ab titers against the second virus. Interestingly, PT and NE adjuvants when administered during the first immunization even prevented original antigenic sin in subsequent immunization without any adjuvants. As an alternative to using adjuvants, we also found that repeated immunization with the second viral strain relieved the effects of original antigenic sin. Taken together, our studies provide at least three ways of overcoming original antigenic sin.cross-reactivity | antigen presentation | memory T-cell activation

show abstract

“…Although an MF59 adjuvanted influenza vaccine for the elderly (FluAd ® , Novartis Vaccines) is approved for use in Europe, it is not yet approved for distribution in the United States. Published data thus far have shown that MF59 adjuvanted vaccine improves immunogenicity against influenza in immunocompromised and elderly populations, [34][35][36] and strengthens immune responses against HBV. 37 Vaccination studies for cytomegalovirus and HIV also support further research into the use of MF59 adjuvant.…”

Section: Discussionmentioning

confidence: 99%

Improving vaccine delivery using novel adjuvant systems

Pichichero¹

2008

Human Vaccines

View full text Add to dashboard Cite

ASO4, a novel adjuvant, contains aluminum hydroxide and monophosphoryl lipid (MPL) (500 mg aluminum hydroxide and 50 mg 3-O-desacyl-4' MPL A). Aluminum hydroxide is an adjuvant known to facilitate vaccine antigen delivery and transport to the draining lymph nodes by creating a 'depot' at the injection site. 2 Like all aluminum adjuvants, aluminum hydroxide helps improve immunogenicity of low molecular weight antigens, which could otherwise clear rapidly from the injection site or draining lymph nodes. 2 MPL, a non-toxic derivative of lipopolysaccharide, improves specific antibody and cell-mediated immune responses to vaccination. 4 With only minimal toxicity, 5 MPL enhances macrophage and B-and Tcell responses, as well as T-helper cell generation. 5,6 AS04 adjuvant has been shown to improve vaccine-induced immune responses in hepatitis B (HBV) and cervical cancer vaccines.In 2004, Boland et al. 7 described a randomized study where healthy subjects received two doses of HBV vaccine with ASO4 adjuvant or three doses of HBV vaccine with aluminum adjuvant. 7 After the first and second dose of ASO4, substantially more subjects were seropositive for anti-HBV antibodies than after the first and third dose of aluminum adjuvanted vaccine (Table 1). Thus, the ASO4 adjuvant provided the potential for an effective two dose HBV vaccine schedule. In addition, after two doses of ASO4 adjuvanted vaccine, geometric mean titers (GMT) were two times higher than those observed with the aluminum adjuvanted vaccine (7,832 mlU/ml vs 3,725 mlU/ml). No serious adverse events (SAEs) related to the vaccinations occurred, and the overall incidence of vaccine-related adverse events (AEs) (e.g., pain, redness and swelling around the injection site) was comparable between groups. 7 For patients undergoing haemodialysis, the Centers for Disease Control recommends stronger or increased doses of HBV vaccine to assure protective immunity. 8 A clinical trial comparing the immune responses of pre-haemodialysis and haemodialysis patients showed four doses of HBV vaccine was more effective with ASO4 adjuvant than with aluminum adjuvant (Table 1). 9 More patients achieved seroprotection at three months (p = 0.005) and remained seroprotected at 36 months with ASO4 adjuvanted vaccine than with aluminum adjuvanted vaccine (p = 0.03, Table 1). 9 At three and seven months post final dose, signficiantly more patients in the HBV-ASO4 adjuvant group had anti-HB concentrations >100 mlU/mL (p < 0.001 and p < 0.04, respectively), and a higher percentage retained these high anti-HB levels at 36 months

show abstract

MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18–60 years of age) with chronic diseases who are at risk of post-influenza complications

Cited by 62 publications

References 16 publications

Safety and Immunogenicity of Two Influenza Virus Subunit Vaccines, with or without MF59 Adjuvant, Administered to Human Immunodeficiency Virus Type 1-Seropositive and -Seronegative Adults

Safety and Immunogenicity of Two Influenza Virus Subunit Vaccines, with or without MF59 Adjuvant, Administered to Human Immunodeficiency Virus Type 1-Seropositive and -Seronegative Adults

Strategies to alleviate original antigenic sin responses to influenza viruses

Improving vaccine delivery using novel adjuvant systems

Contact Info

Product

Resources

About